Benjamin A. Turner

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

Identification and Validation of Novel Small Molecule Disruptors of HuR-mRNA Interaction

Xiaoqing Wu, Lan Lan, David Michael Wilson et al. · ACS Chemical Biology · 2015 · 152 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 77 citations

Medicine, Oncology, Pharmacology +17

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1

Erik L. Brincks, James Truslow Adams, Lifu Wang et al. · Oncotarget · 2020 · 38 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1

Lauren G. Monovich, Keith A. Koch, Robin Burgis et al. · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · 2009 · 30 citations

Medicine, Cardiology, Molecular Biology +9